ALX Oncology Holdings Inc. (NASDAQ:ALXO) Receives Average Rating of "Moderate Buy" from Analysts

Key Points

• ALX Oncology Holdings Inc. has received a consensus rating of "Moderate Buy", with one analyst recommending a hold and five analysts offering buy ratings.
• The average 12-month price target set by analysts for ALX Oncology is $3.30, despite recent downward adjustments by some firms.
• Hedge funds hold approximately 97.97% of ALX Oncology's stock, with significant increases in positions by several institutional investors in the past quarters.

Shares of ALX Oncology Holdings Inc. (NASDAQ:ALXO - Get Free Report) have been given a consensus rating of "Moderate Buy" by the six research firms that are covering the company, Marketbeat.com reports. One equities research analyst has rated the stock with a hold rating and five have issued a buy rating on the company. The average twelve-month target price among brokerages that have issued a report on the stock in the last year is $3.30.

Several equities analysts have weighed in on ALXO shares. UBS Group lowered their price target on shares of ALX Oncology from $1.20 to $1.00 and set a "buy" rating on the stock in a report on Wednesday, May 21st. HC Wainwright reduced their price objective on shares of ALX Oncology from $5.00 to $2.00 and set a "buy" rating on the stock in a research report on Friday, May 9th. Finally, Wall Street Zen cut ALX Oncology from a "hold" rating to a "sell" rating in a report on Friday, June 6th.

Hedge Funds Weigh In On ALX Oncology

Several large investors have recently modified their holdings of the stock. Northern Trust Corp increased its position in shares of ALX Oncology by 7.3% during the 4th quarter. Northern Trust Corp now owns 343,066 shares of the company's stock valued at $573,000 after purchasing an additional 23,324 shares during the last quarter. Two Sigma Investments LP raised its holdings in shares of ALX Oncology by 6.7% in the fourth quarter. Two Sigma Investments LP now owns 704,131 shares of the company's stock worth $1,176,000 after buying an additional 44,072 shares during the period. Nuveen Asset Management LLC raised its holdings in shares of ALX Oncology by 55.6% in the fourth quarter. Nuveen Asset Management LLC now owns 164,790 shares of the company's stock worth $275,000 after buying an additional 58,896 shares during the period. Invesco Ltd. purchased a new stake in shares of ALX Oncology in the first quarter worth approximately $46,000. Finally, Bridgeway Capital Management LLC purchased a new stake in shares of ALX Oncology in the fourth quarter worth approximately $125,000. Institutional investors own 97.97% of the company's stock.

ALX Oncology Price Performance

NASDAQ ALXO remained flat at $1.02 during mid-day trading on Friday. 15,725 shares of the company were exchanged, compared to its average volume of 857,047. ALX Oncology has a 52 week low of $0.40 and a 52 week high of $2.36. The firm has a market cap of $54.62 million, a PE ratio of -0.47 and a beta of 1.11. The business's 50-day moving average price is $0.67 and its two-hundred day moving average price is $0.66. The company has a current ratio of 4.52, a quick ratio of 4.52 and a debt-to-equity ratio of 0.11.

ALX Oncology (NASDAQ:ALXO - Get Free Report) last announced its quarterly earnings data on Tuesday, August 12th. The company reported ($0.49) earnings per share for the quarter, missing analysts' consensus estimates of ($0.46) by ($0.03). As a group, equities research analysts expect that ALX Oncology will post -2.76 earnings per share for the current year.

ALX Oncology Company Profile

ALX Oncology Holdings Inc, a clinical-stage immuno-oncology company, focuses on developing therapies for cancer patients in the United States. The company's lead product candidate is Evorpacept, a CD47 blocking therapeutic biologic in development as a combination therapy with other anti-cancer agents, including ASPEN-06, under Phase 2 clinical study for treating Gastric/GEJ cancer; ASPEN-07, under Phase 1 clinical study for treating urothelial cancer; and ASPEN-03 and ASPEN-04, both under Phase 2 clinical study for treating head and neck squamous cell carcinoma.